James M. Frates, CFO of Amylyx Pharmaceuticals ($AMLX), sold common shares on the open market five times over the past year for a total of $396 thousand. His most recent sale occurred on March 2, 2026. These transactions rank 6,963rd among 11,678 insiders in our database, well below the average sale amount of $8.6 million across 6.4 transactions per insider. Frates made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 5, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | A | Stock Option (right to buy) | 143985 | $0.00 | 143,985.0000 | 109,819,569 | 9999.99% | 0.13% |
| March 5, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | A | Common Stock | 95990 | $0.00 | 388,159.0000 | 109,819,569 | 32.85% | 0.09% |
| March 2, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | S | Common Stock | 7909 | $14.52 | 292,169.0000 | 109,819,569 | 2.64% | 0.01% |
| Feb. 2, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | S | Common Stock | 3557 | $14.65 | 300,078.0000 | 109,819,569 | 1.17% | 0.00% |
| Jan. 6, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | S | Common Stock | 3326 | $11.11 | 303,635.0000 | 109,819,569 | 1.08% | 0.00% |
| Sept. 30, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | S | Common Stock | 10558 | $14.65 | 306,961.0000 | 88,602,468 | 3.33% | 0.01% |
| July 31, 2025 | Sage Therapeutics, Inc. | $SAGE | FRATES JAMES M | Not found | D | Stock Option (Right to Buy) | 19154 | $0.00 | 0.0000 | 62,784,397 | 100.00% | 0.03% |
| July 31, 2025 | Sage Therapeutics, Inc. | $SAGE | FRATES JAMES M | Not found | U | Common Stock | 2845 | $0.00 | 0.0000 | 62,784,397 | 100.00% | 0.00% |
| July 31, 2025 | Sage Therapeutics, Inc. | $SAGE | FRATES JAMES M | Not found | D | Stock Option (Right to Buy) | 21500 | $0.00 | 0.0000 | 62,784,397 | 100.00% | 0.03% |
| June 11, 2025 | Sage Therapeutics, Inc. | $SAGE | FRATES JAMES M | Not found | A | Stock Option (Right to Buy) | 21500 | $0.00 | 21,500.0000 | 61,480,947 | 9999.99% | 0.03% |
| March 31, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | S | Common Stock | 10896 | $3.47 | 317,519.0000 | 88,602,468 | 3.32% | 0.01% |
| March 6, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | A | Stock Option (right to buy) | 102630 | $0.00 | 102,630.0000 | 88,602,468 | 9999.99% | 0.12% |
| March 6, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | A | Common Stock | 68420 | $0.00 | 328,415.0000 | 88,602,468 | 26.32% | 0.08% |
| Jan. 3, 2025 | Sage Therapeutics, Inc. | $SAGE | FRATES JAMES M | Not found | A | Stock Options (Right to buy) | 19154 | $0.00 | 19,154.0000 | 0 | 9999.99% | 0.00% |
| Sept. 12, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | P | Common Stock | 40000 | $2.53 | 259,995.0000 | 0 | 18.18% | 0.00% |
| Aug. 23, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | M | Common Stock | 18165 | $6.88 | 93,323.0000 | 0 | 24.17% | 0.00% |
| Aug. 23, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | M | Stock Option (right to buy) | 18165 | $0.00 | 363,835.0000 | 0 | 4.76% | 0.00% |
| June 10, 2024 | Sage Therapeutics, Inc. | $SAGE | FRATES JAMES M | Not found | A | Stock Option (Right to Buy) | 12500 | $0.00 | 12,500.0000 | 0 | 9999.99% | 0.00% |
| April 16, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | A | Stock Option (right to buy) | 120000 | $0.00 | 120,000.0000 | 0 | 9999.99% | 0.00% |
| April 16, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | A | Common Stock | 91180 | $0.00 | 252,495.0000 | 0 | 56.52% | 0.00% |
| March 5, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | S | Common Stock | 1792 | $18.73 | 161,315.0000 | 0 | 1.10% | 0.00% |
| Feb. 26, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | A | Common Stock | 40000 | $0.00 | 163,107.0000 | 0 | 32.49% | 0.00% |
| Feb. 26, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | A | Stock Option (right to buy) | 60000 | $0.00 | 60,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 9, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | S | Common Stock | 2716 | $16.33 | 123,107.0000 | 0 | 2.16% | 0.00% |
| Jan. 3, 2024 | Sage Therapeutics, Inc. | $SAGE | FRATES JAMES M | Not found | A | Stock Options (Right to buy) | 4925 | $0.00 | 4,925.0000 | 0 | 9999.99% | 0.00% |
| Oct. 31, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | G | Common Stock | 11072 | $0.00 | 125,823.0000 | 0 | 9.65% | 0.00% |
| Aug. 23, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | M | Common Stock | 18165 | $6.88 | 125,823.0000 | 0 | 16.87% | 0.00% |
| Aug. 23, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | M | Stock Option (right to buy) | 18165 | $0.00 | 363,835.0000 | 0 | 4.76% | 0.00% |
| May 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | M | Common Stock | 32500 | $6.88 | 107,658.0000 | 0 | 43.24% | 0.00% |
| May 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | S | Common Stock | 500 | $27.60 | 75,158.0000 | 0 | 0.66% | 0.00% |
| May 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | S | Common Stock | 32000 | $26.93 | 75,658.0000 | 0 | 29.72% | 0.00% |
| May 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | M | Stock Option (right to buy) | 32500 | $0.00 | 382,000.0000 | 0 | 7.84% | 0.00% |
| Jan. 6, 2022 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | C | Series C-1 Preferred Stock | 19482 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Jan. 6, 2022 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | C | Common Stock | 19482 | $0.00 | 19,482.0000 | 0 | 9999.99% | 0.00% |
| March 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | A | Common Stock | 21667 | $0.00 | 55,676.0000 | 0 | 63.71% | 0.00% |
| March 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | M | Stock Option (right to buy) | 32500 | $0.00 | 414,500.0000 | 0 | 7.27% | 0.00% |
| March 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | M | Common Stock | 32500 | $6.88 | 66,509.0000 | 0 | 95.56% | 0.00% |
| March 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | S | Common Stock | 30796 | $31.86 | 35,713.0000 | 0 | 46.30% | 0.00% |
| March 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | S | Common Stock | 1704 | $32.46 | 34,009.0000 | 0 | 4.77% | 0.00% |
| March 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | A | Stock Option (right to buy) | 97500 | $0.00 | 97,500.0000 | 0 | 9999.99% | 0.00% |
| March 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | A | Stock Option (right to buy) | 97500 | $0.00 | 97,500.0000 | 0 | 9999.99% | 0.00% |
| March 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | S | Common Stock | 30796 | $31.86 | 3,213.0000 | 0 | 90.55% | 0.00% |
| March 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | S | Common Stock | 1704 | $32.46 | 1,509.0000 | 0 | 53.03% | 0.00% |
| March 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | A | Common Stock | 21667 | $0.00 | 23,176.0000 | 0 | 1435.85% | 0.00% |
| Jan. 6, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | S | Common Stock | 1836 | $36.08 | 34,831.0000 | 0 | 5.56% | 0.00% |
| Jan. 6, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | S | Common Stock | 822 | $36.79 | 34,009.0000 | 0 | 2.48% | 0.00% |
| Dec. 30, 2022 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 447,000.0000 | 0 | 1.11% | 0.00% |
| Dec. 30, 2022 | Amylyx Pharmaceuticals, Inc. | $AMLX | FRATES JAMES M | Chief Financial Officer | M | Common Stock | 5000 | $6.88 | 36,667.0000 | 0 | 15.79% | 0.00% |